## Jorg Kleeff

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8824115/publications.pdf

Version: 2024-02-01

468 papers

27,837 citations

82 h-index 146 g-index

525 all docs 525 docs citations

525 times ranked

29459 citing authors

#	Article	IF	CITATIONS
1	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	30.5	1,301
2	Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Medicine, 2010, 7, e1000267.	8.4	1,300
3	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	17.8	762
4	Most Pancreatic Cancer Resections are R1 Resections. Annals of Surgical Oncology, 2008, 15, 1651-1660.	1.5	574
5	The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 454-467.	17.8	535
6	Systematic Review and Meta-Analysis of the Role of Defunctioning Stoma in Low Rectal Cancer Surgery. Annals of Surgery, 2008, 248, 52-60.	4.2	512
7	Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet, The, 2011, 377, 1514-1522.	13.7	485
8	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 2015, 15, 8-18.	1.1	404
9	The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2008, 6, 1155-1161.	4.4	361
10	Distal Pancreatectomy. Annals of Surgery, 2007, 245, 573-582.	4.2	358
11	StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut, 2012, 61, 172-178.	12.1	358
12	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349
13	Chronic pancreatitis. Nature Reviews Disease Primers, 2017, 3, 17060.	30.5	339
14	The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer Journal of Clinical Investigation, 1998, 102, 1662-1673.	8.2	316
15	Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. British Journal of Surgery, 2007, 94, 265-273.	0.3	284
16	Periostin Creates a Tumor-Supportive Microenvironment in the Pancreas by Sustaining Fibrogenic Stellate Cell Activity. Gastroenterology, 2007, 132, 1447-1464.	1.3	273
17	Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767). Annals of Surgery, 2016, 263, 440-449.	4.2	257
18	Cancer-Stellate Cell Interactions Perpetuate the Hypoxia-Fibrosis Cycle in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2009, 11, 497-508.	5 <b>.</b> 3	253

#	Article	IF	Citations
19	The TGF- $\hat{l}^2$ signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 1999, 18, 5363-5372.	5.9	248
20	Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48, 558-564.	12.1	248
21	Is There Still a Role for Total Pancreatectomy?. Annals of Surgery, 2007, 246, 966-975.	4.2	240
22	Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. British Journal of Surgery, 2008, 95, 627-635.	0.3	237
23	Surgery for Recurrent Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2007, 245, 566-572.	4.2	217
24	Inter―and intraâ€ŧumoural heterogeneity in cancerâ€associated fibroblasts of human pancreatic ductal adenocarcinoma. Journal of Pathology, 2019, 248, 51-65.	4.5	215
25	Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Molecular Cancer, 2015, 14, 94.	19.2	210
26	Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2006, 14, 118-127.	1.5	201
27	Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12890-12895.	7.1	198
28	Pancreatic cancer microenvironment. International Journal of Cancer, 2007, 121, 699-705.	5.1	190
29	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	4.2	189
30	Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene, 2005, 24, 4421-4432.	5.9	187
31	Complications of pancreatic surgery. Hpb, 2005, 7, 99-108.	0.3	179
32	Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology, 2008, 47, 511-520.	7.3	173
33	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. Nature Methods, 2014, 11, 1161-1169.	19.0	170
34	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 2015, 21, 2325-2337.	7.0	170
35	Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology, 1999, 116, 1202-1216.	1.3	160
36	Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes. Oncology, 2002, 62, 354-362.	1.9	152

#	Article	IF	Citations
37	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1625-1639.e2.	1.3	152
38	Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology, 2012, 55, 287-297.	7.3	147
39	Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. Journal of Pathology, 2006, 208, 673-685.	4.5	142
40	Renal Cancer Cell Metastasis Into the Pancreas. Pancreas, 2005, 30, 218-222.	1.1	141
41	Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues. Nature Protocols, 2009, 4, 37-43.	12.0	141
42	Detection and localization of MIP-3?/LARC/exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer., 1999, 81, 650-657.		139
43	Id-1 and Id-2 Are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis. American Journal of Pathology, 1999, 155, 815-822.	3.8	137
44	Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Laboratory Investigation, 2005, 85, 1276-1291.	3.7	137
45	Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling. Molecular Cancer Therapeutics, 2014, 13, 1758-1771.	4.1	135
46	The Role of Diagnostic Laparoscopy in Pancreatic and Periampullary Malignancies. Journal of the American College of Surgeons, 1998, 186, 675-682.	0.5	133
47	The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Letters, 2001, 503, 151-157.	2.8	133
48	Middle Segmental Pancreatic Resection. Annals of Surgery, 2006, 244, 909-920.	4.2	132
49	Effect of Antecolic Reconstruction on Delayed Gastric Emptying After the Pylorus-Preserving Whipple Procedure. Archives of Surgery, 2005, 140, 1094.	2.2	131
50	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. International Journal of Cancer, 2000, 88, 12-20.	5.1	130
51	Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer, 2009, 9, 463.	2.6	127
52	Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters, 2008, 268, 98-109.	7.2	126
53	Autoantibodies Against the Exocrine Pancreas in Autoimmune Pancreatitis: Gene and Protein Expression Profiling and Immunoassays Identify Pancreatic Enzymes as a Major Target of the Inflammatory Process. American Journal of Gastroenterology, 2010, 105, 2060-2071.	0.4	126
54	Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene, 2002, 21, 6059-6070.	5.9	123

#	Article	IF	CITATIONS
55	Cannabinoids in pancreatic cancer: Correlation with survival and pain. International Journal of Cancer, 2008, 122, 742-750.	5.1	121
56	Fast Trackâ€"Different Implications in Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2007, 11, 880-887.	1.7	116
57	Pancreatic Cancer. Pancreas, 2006, 33, 111-118.	1.1	115
58	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 301-316.	3.0	114
59	Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut, 2015, 64, 1921-1935.	12.1	112
60	Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. International Journal of Cancer, 2000, 86, 399-407.	5.1	109
61	Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery, 2008, 143, 20-28.	1.9	109
62	Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. Langenbeck's Archives of Surgery, 2015, 400, 167-181.	1.9	109
63	Gastric emptying following pylorus-preserving whipple and duodenum-preserving pancreatic head resection in patients with chronic pancreatitis. American Journal of Surgery, 1997, 173, 257-263.	1.8	108
64	Surgical Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences, 2008, 1138, 169-180.	3.8	105
65	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.	2.6	103
66	Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. Cancers, 2018, 10, 3.	3.7	103
67	Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice. Journal of Clinical Investigation, 2013, 123, 2231-2243.	8.2	103
68	Smad6 Suppresses TGF-Î <sup>2</sup> -Induced Growth Inhibition in COLO-357 Pancreatic Cancer Cells and Is Overexpressed in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 1999, 255, 268-273.	2.1	102
69	B7-H3 and Its Role in Antitumor Immunity. Clinical and Developmental Immunology, 2010, 2010, 1-7.	3.3	101
70	Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biology and Therapy, 2008, 7, 1352-1359.	3.4	98
71	Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdominal Imaging, 2011, 36, 179-184.	2.0	98
72	Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Molecular Carcinogenesis, 2002, 35, 138-147.	2.7	92

#	Article	IF	Citations
73	Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology, 2003, 124, 1830-1845.	1.3	92
74	Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. International Journal of Cancer, 2004, 110, 668-676.	5.1	91
75	Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. American Journal of Surgery, 2008, 195, 221-228.	1.8	91
76	Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Molecular Cancer Therapeutics, 2009, 8, 1494-1504.	4.1	91
77	Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Molecular Cancer, 2010, 9, 88.	19.2	90
78	Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells. Annals of Surgery, 2005, 242, 224-234.	4.2	89
79	Glutamate increases pancreatic cancer cell invasion and migration <i>via ⟨i⟩ AMPA receptor activation and Krasâ€MAPK signaling. International Journal of Cancer, 2011, 129, 2349-2359.</i>	5.1	88
80	Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Scientific Reports, 2017, 7, 41064.	3.3	88
81	Overexpression of activin A in stage IV colorectal cancer. Gut, 2001, 49, 409-417.	12.1	87
82	Resection of Primary Pancreatic Cancer and Liver Metastasis: A Systematic Review. Digestive Surgery, 2008, 25, 473-480.	1.2	87
83	Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. International Journal of Cancer, 2007, 121, 21-32.	5.1	85
84	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncology, 2020, 6, 1733.	7.1	85
85	Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biology and Therapy, 2005, 4, 740-746.	3.4	84
86	Epiregulin Is Up-Regulated in Pancreatic Cancer and Stimulates Pancreatic Cancer Cell Growth. Biochemical and Biophysical Research Communications, 2000, 273, 1019-1024.	2.1	82
87	Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Molecular Cancer, 2005, 4, 14.	19.2	81
88	Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Letters, 2001, 163, 71-81.	7.2	79
89	ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. Journal of Cellular and Molecular Medicine, 2007, 11, 1162-1174.	3.6	79
90	AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-Î <sup>2</sup> -mediated ERK signaling. Oncogene, 2010, 29, 5146-5158.	5.9	78

#	Article	IF	CITATIONS
91	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, 150, 513-525.e10.	1.3	78
92	Molecular Aspects of Pancreatic Cancer and Future Perspectives. Digestive Surgery, 1999, 16, 281-290.	1.2	77
93	The Stem Cell Factor–c-kit System and Mast Cells in Human Pancreatic Cancer. Laboratory Investigation, 2002, 82, 1481-1492.	3.7	77
94	Suppression of transforming growth factor $\hat{A}$ signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations. Gut, 2007, 56, 685-692.	12.1	77
95	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Annals of Surgical Oncology, 2015, 22, 1212-1220.	1.5	77
96	Enhanced Expression of the Type II Transforming Growth Factor-Î <sup>2</sup> Receptor Is Associated with Decreased Survival in Human Pancreatic Cancer. Pancreas, 1999, 19, 370-376.	1.1	76
97	Growth factors and their receptors in pancreatic cancer. Teratogenesis, Carcinogenesis, and Mutagenesis, 2001, 21, 27-44.	0.8	76
98	Multicenter Double-Blinded Randomized Controlled Trial of Standard Abdominal Wound Edge Protection With Surgical Dressings Versus Coverage With a Sterile Circular Polyethylene Drape for Prevention of Surgical Site Infections. Annals of Surgery, 2014, 260, 730-739.	4.2	76
99	Influences of the lysosomal associated membrane proteins (Lampâ€1, Lampâ€2) and Macâ€2 binding protein (Macâ€2â€BP) on the prognosis of pancreatic carcinoma. Cancer, 2002, 94, 228-239.	4.1	75
100	Tumor-Suppressor Function of SPARC-Like Protein 1/Hevin in Pancreatic Cancer. Neoplasia, 2007, 9, 8-17.	5.3	74
101	Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. British Journal of Surgery, 2017, 104, e182-e188.	0.3	74
102	Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Annals of Surgical Oncology, 2018, 25, 1440-1447.	1.5	73
103	Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis. Annals of Surgical Oncology, 2019, 26, 772-781.	1.5	73
104	Mast cell distribution and activation in chronic pancreatitis. Human Pathology, 2001, 32, 1174-1183.	2.0	72
105	Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Letters, 2015, 356, 721-732.	7.2	72
106	The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance. Current Molecular Medicine, 2012, 12, 288-303.	1.3	71
107	Mitogen-Activated Protein Kinases and Chemoresistance in Pancreatic Cancer Cells. Journal of Surgical Research, 2006, 136, 325-335.	1.6	70
108	An audit of outcomes of a series of periampullary carcinomas. European Journal of Surgical Oncology, 2009, 35, 187-191.	1.0	70

#	Article	lF	Citations
109	Precancerous lesions of the biliary tree. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 285-297.	2.4	70
110	Up-regulation of Transforming Growth Factor (TGF)- $\hat{l}^2$ Receptors by TGF- $\hat{l}^2$ 1 in COLO-357 Cells. Journal of Biological Chemistry, 1998, 273, 7495-7500.	3.4	68
111	Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene, 2004, 23, 71-81.	5.9	68
112	International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis. Pancreatology, 2020, 20, 149-157.	1.1	68
113	Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology, 2003, 125, 98-106.	1.3	66
114	Enhanced expression of 14-3-3 sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 2004, 25, 1575-1585.	2.8	65
115	HAnd Suture Versus STApling for Closure of Loop Ileostomy (HASTA Trial). Annals of Surgery, 2012, 256, 828-836.	4.2	65
116	Metastasis to the Pancreas: Characterization by Morphology and Contrast Enhancement Features on CT and MRI. Pancreatology, 2008, 8, 199-203.	1.1	64
117	Molecular mechanism of pancreatic cancerâ€"understanding proliferation, invasion, and metastasis. Langenbeck's Archives of Surgery, 2010, 395, 295-308.	1.9	64
118	Transfection of the type I TGF- $\hat{l}^2$ receptor restores TGF- $\hat{l}^2$ responsiveness in pancreatic cancer. , 1998, 78, 255-260.		63
119	Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells. Cancer Biology and Therapy, 2007, 6, 367-376.	3.4	63
120	Hypothetical Progression Model of Pancreatic Cancer With Origin in the Centroacinar-Acinar Compartment. Pancreas, 2007, 35, 212-217.	1.1	62
121	Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. British Journal of Cancer, 2007, 97, 1106-1115.	6.4	62
122	Molecular Pathogenesis of Pancreatic Cancer: Advances and Challenges. Current Molecular Medicine, 2007, 7, 504-521.	1.3	61
123	Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. International Journal of Cancer, 2001, 94, 268-274.	5.1	60
124	Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Cancer Research, 2004, 64, 3599-3606.	0.9	60
125	Hedgehog Signaling in the Normal and Diseased Pancreas. Pancreas, 2006, 32, 119-129.	1.1	60
126	Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1461-1470.	7.0	60

#	Article	IF	Citations
127	FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. International Journal of Cancer, 2006, 118, 43-54.	5.1	59
128	Prevention and Treatment of Complications in Pancreatic Cancer Surgery. Digestive Surgery, 1999, 16, 327-336.	1.2	58
129	Solo-surgical laparoscopic cholecystectomy with a joystick-guided camera device: a case–control study. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 164-170.	2.4	58
130	Stable Transfection of a Glypican-1 Antisense Construct Decreases Tumorigenicity in PANC-1 Pancreatic Carcinoma Cells. Pancreas, 1999, 19, 281-288.	1.1	57
131	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut, 2016, 65, 647-657.	12.1	57
132	Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. Journal of Surgical Research, 2015, 197, 91-100.	1.6	56
133	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut, 2017, 66, 314-322.	12.1	56
134	Identification of Disease-specific Genes in Chronic Pancreatitis Using DNA Array Technology. Annals of Surgery, 2001, 234, 769-779.	4.2	55
135	Glypican-1 antisense transfection modulates TGF- $\hat{l}^2$ -dependent signaling in Colo-357 pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2004, 320, 1148-1155.	2.1	55
136	Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Frontiers in Physiology, 2013, 4, 246.	2.8	55
137	Concomitant over-expression of activin/inhibin $\hat{l}^2$ subunits and their receptors in human pancreatic cancer. , 1998, 77, 860-868.		53
138	Altered Expression and Localization of the Tight Junction Protein ZO-1 in Primary and Metastatic Pancreatic Cancer. Pancreas, 2001, 23, 259-265.	1.1	53
139	Induction and expression of $\hat{l}^2$ ig-h3 in pancreatic cancer cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1588, 1-6.	3.8	53
140	Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. British Journal of Surgery, 2009, 96, 711-719.	0.3	53
141	Distribution of Indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis. Journal of Endocrinology, 2003, 178, 467-478.	2.6	52
142	Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biology and Therapy, 2007, 6, 218-227.	3.4	52
143	MALDI Imaging Mass Spectrometry for In Situ Proteomic Analysis of Preneoplastic Lesions in Pancreatic Cancer. PLoS ONE, 2012, 7, e39424.	2.5	52
144	Palliative resections versus palliative bypass procedures in pancreatic cancerâ€"a systematic review. American Journal of Surgery, 2012, 203, 496-502.	1.8	51

#	Article	IF	CITATIONS
145	Comparison of $3\hat{a}\in^2$ -deoxy- $3\hat{a}\in^2$ -[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 846-851.	6.4	51
146	Canonical NFâ€ÎºB signaling in hepatocytes acts as a tumorâ€suppressor in hepatitis B virus surface antigenâ€driven hepatocellular carcinoma by controlling the unfolded protein response. Hepatology, 2016, 63, 1592-1607.	7.3	51
147	Enhanced Expression of Silencer of Death Domains (SODD/BAG-4) in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 2000, 271, 409-413.	2.1	49
148	Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit. Molecular Cancer Therapeutics, 2011, 10, 1918-1928.	4.1	49
149	Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors. Clinical Colorectal Cancer, 2015, 14, 281-290.	2.3	49
150	Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. British Journal of Cancer, 2008, 99, 760-767.	6.4	48
151	Wound Edge Protectors in Open Abdominal Surgery to Reduce Surgical Site Infections: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0121187.	2.5	48
152	The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. British Journal of Cancer, 2016, 115, 887-894.	6.4	48
153	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery, 2020, 168, 72-84.	1.9	48
154	RUNX3 expression in primary and metastatic pancreatic cancer. Journal of Clinical Pathology, 2004, 57, 294-299.	2.0	47
155	Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells. PLoS ONE, 2008, 3, e1701.	2.5	47
156	Fas and Fas-Ligand Expression in Human Pancreatic Cancer. Annals of Surgery, 2000, 231, 368-379.	4.2	46
157	Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. Journal of Clinical Pathology, 2006, 60, 885-895.	2.0	46
158	Perioperative and follow-up results after central pancreatic head resection (Berne technique) in a consecutive series of patients with chronic pancreatitis. American Journal of Surgery, 2008, 196, 364-372.	1.8	46
159	How fibrosis influences imaging and surgical decisions in pancreatic cancer. Frontiers in Physiology, 2012, 3, 389.	2.8	46
160	Human Hepatocytes: Isolation, Culture, and Quality Procedures. Methods in Molecular Biology, 2012, 806, 99-120.	0.9	46
161	Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomedicine and Pharmacotherapy, 2014, 68, 737-743.	<b>5.</b> 6	46
162	Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy. Diseases of the Colon and Rectum, 2002, 45, 1242-1248.	1.3	45

#	Article	IF	CITATIONS
163	T-tube or no T-tube in reconstruction of the biliary tract during orthotopic liver transplantation - systematic review and meta-analysis. Liver Transplantation, 2010, 16, NA-NA.	2.4	45
164	Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clinical Cancer Research, 1999, 5, 2840-7.	7.0	45
165	Expression of the Multidrug-Resistance 1 (MDR1) Gene and Prognosis in Human Pancreatic Cancer. Pancreas, 2000, 21, 240-247.	1.1	44
166	From tissue turnover to the cell of origin for pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 467-472.	17.8	44
167	Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 427-433.	1.7	44
168	Multimodal Molecular Imaging of Integrin $\hat{l}\pm <\text{sub}>v \hat{l}^2 <\text{sub}>3 $ for In Vivo Detection of Pancreatic Cancer. Journal of Nuclear Medicine, 2014, 55, 446-451.	5.0	43
169	Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. Gut, 2018, 67, 146-156.	12.1	43
170	Pancreatic Cancer: Factors Regulating Tumor Development, Maintenance and Metastasis. Pancreatology, 2001, 1, 517-524.	1.1	42
171	Effects of STI571 (gleevec) on pancreatic cancer cell growth. Molecular Cancer, 2003, 2, 32.	19.2	42
172	In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors. Journal of Nuclear Medicine, 2008, 49, 1437-1444.	5.0	42
173	Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Letters, 2009, 277, 72-81.	7.2	42
174	Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Molecular Cancer, 2012, 11, 19.	19.2	42
175	Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. Journal of Clinical Pathology, 2006, 59, 580-584.	2.0	41
176	Simultaneous/Incidental Cholecystectomy During Gastric/Esophageal Resection: Systematic Analysis of Risks and Benefits. World Journal of Surgery, 2010, 34, 1008-1014.	1.6	41
177	Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2011, 13, 1026-IN24.	5.3	41
178	Immunotherapy of pancreatic cancer. Progress in Molecular Biology and Translational Science, 2019, 164, 189-216.	1.7	41
179	The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis. Pancreatology, 2020, 20, 762-771.	1.1	41
180	Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Research, 2006, 26, 3265-73.	1.1	40

#	Article	IF	Citations
181	Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors?. American Journal of Gastroenterology, 2009, 104, 171-181.	0.4	39
182	ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. Journal of Surgical Oncology, 2010, 101, 564-569.	1.7	39
183	International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis.  Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology,	1.1	39
184	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose–Response Relationships. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1009-1018.	<b>2.</b> 5	39
185	Moxifloxacin penetration into human gastrointestinal tissues. Journal of Antimicrobial Chemotherapy, 2004, 53, 875-877.	3.0	38
186	Management of Early Hemorrhage from Pancreatic Anastomoses after Pancreaticoduodenectomy. Digestive Surgery, 2006, 23, 203-208.	1.2	38
187	Is there an advantage in performing a pancreas-preserving total duodenectomy in duodenal adenomatosis?. American Journal of Surgery, 2008, 195, 741-748.	1.8	38
188	Combined blockade of TGf- $\hat{l}^21$ and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunology, Immunotherapy, 2020, 69, 1477-1492.	4.2	38
189	Aberrant Gata-3 Expression in Human Pancreatic Cancer. Journal of Histochemistry and Cytochemistry, 2006, 54, 161-169.	2.5	37
190	Surgical Treatment of Pancreatic Cancer. Journal of the American College of Surgeons, 2007, 205, S81-S86.	0.5	37
191	Pigment Epithelium-Derived Factor Associates With Neuropathy and Fibrosis in Pancreatic Cancer. American Journal of Gastroenterology, 2011, 106, 968-980.	0.4	37
192	Fluconazole Penetration into the Pancreas. Antimicrobial Agents and Chemotherapy, 2000, 44, 2569-2571.	3.2	36
193	Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. European Journal of Surgical Oncology, 2007, 33, 817-823.	1.0	36
194	Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry. Gastric Cancer, 2016, 19, 713-722.	5.3	36
195	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Gut, 2021, 70, gutjnl-2019-319990.	12.1	36
196	Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. Journal of Translational Medicine, 2007, 5, 63.	4.4	35
197	Neoadjuvant therapy for pancreatic cancer. British Journal of Surgery, 2007, 94, 261-262.	0.3	35
198	Autoimmune Pancreatocholangitis, Non-Autoimmune Pancreatitis and Primary Sclerosing Cholangitis: A Comparative Morphological and Immunological Analysis. PLoS ONE, 2008, 3, e2539.	2.5	35

#	Article	IF	Citations
199	Pancreatic Islet and Stellate Cells Are the Main Sources of Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Pancreatic Cancer. Pancreatology, 2009, 9, 165-172.	1.1	35
200	Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study. Hpb, 2019, 21, 1641-1647.	0.3	35
201	Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatology Research, 2003, 26, 192-198.	3.4	34
202	Still any role for transduodenal local excision in tumors of the papilla of Vater?. Journal of Hepato-Biliary-Pancreatic Surgery, 2004, 11, 239-44.	2.0	34
203	Microcystic tubulopapillary carcinoma of the pancreas: a new tumor entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 447-453.	2.8	34
204	Expression and differential signaling of heregulins in pancreatic cancer cells. International Journal of Cancer, 2007, 120, 514-523.	5.1	34
205	Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biology and Therapy, 2009, 8, 1527-1533.	3.4	34
206	Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. International Journal of Colorectal Disease, 2009, 24, 57-67.	2.2	34
207	Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biology and Therapy, 2010, 10, 54-64.	3.4	34
208	Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Scientific Reports, 2020, 10, 4444.	3.3	34
209	Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. Lipids in Health and Disease, 2021, 20, 58.	3.0	34
210	Hsulf-1 regulates growth and invasion of pancreatic cancer cells. Journal of Clinical Pathology, 2006, 59, 1052-1058.	2.0	33
211	Autoimmune pancreatitis associated with a large pancreatic pseudocyst. World Journal of Gastroenterology, 2006, 12, 5904.	3.3	33
212	Localization of the human hedgehogâ€interacting protein (Hip) in the normal and diseased pancreas. Molecular Carcinogenesis, 2005, 42, 183-192.	2.7	32
213	Decrease of Global Methylation Improves Significantly Hepatic Differentiation of Ad-MSCs: Possible Future Application for Urea Detoxification. Cell Transplantation, 2013, 22, 119-131.	2.5	32
214	Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Oncotarget, 2015, 6, 32154-32160.	1.8	32
215	Cyclooxygenase 2 Expression in Chronic Pancreatitis: Correlation with Stage of the Disease and Diabetes mellitus. Digestion, 2001, 64, 240-247.	2.3	31
216	Update on pancreatic cancer and alcohol-associated risk. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, S69-S75.	2.8	31

#	Article	IF	Citations
217	Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers, 2020, 12, 3770.	3.7	31
218	Loss of heterozygosity in the HLA class I region in human pancreatic cancer. Tissue Antigens, 2004, 64, 696-702.	1.0	30
219	Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochemical and Biophysical Research Communications, 2010, 401, 422-428.	2.1	30
220	Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology, 2004, 25, 203-10.	3.3	30
221	Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Digestive Diseases and Sciences, 1999, 44, 1793-1802.	2.3	29
222	MOESIN DEPENDENT CYTOSKELETON REMODELING IS ASSOCIATED WITH AN ANAPLASTIC PHENOTYPE OF PANCREATIC CANCER. Journal of Cellular and Molecular Medicine, 2009, 14, 1166-79.	3.6	29
223	Colorectal cancer surgery remains effective with rising patient age. International Journal of Colorectal Disease, 2014, 29, 971-979.	2.2	29
224	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. International Journal of Epidemiology, 2018, 47, 473-483.	1.9	29
225	Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. Oncotarget, 2016, 7, 11424-11433.	1.8	29
226	Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Therapy, 2002, 9, 522-532.	4.6	28
227	Management of Pain in Small Duct Chronic Pancreatitis. Journal of Gastrointestinal Surgery, 2006, 10, 227-233.	1.7	28
228	Proliferation of Colo-357 Pancreatic Carcinoma Cells and Survival of Patients With Pancreatic Carcinoma Are Not Altered by Insulin Glargine. Diabetes Care, 2008, 31, 1105-1111.	8.6	28
229	The impact of different types of surgery in pancreatic cancer. European Journal of Surgical Oncology, 1999, 25, 124-131.	1.0	27
230	Second-Look Operation for Unresectable Pancreatic Ductal Adenocarcinoma at a High-Volume Center. Annals of Surgical Oncology, 2008, 15, 186-192.	1.5	27
231	Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis. Gut, 2019, 68, 2007-2018.	12.1	27
232	Evidence-Based Surgical Treatments for Chronic Pancreatitis. Deutsches Ärzteblatt International, 2016, 113, 489-96.	0.9	27
233	DOC-2/hDab2 Expression Is Up-Regulated in Primary Pancreatic Cancer but Reduced in Metastasis. Laboratory Investigation, 2001, 81, 863-873.	3.7	26
234	Cystic colon duplication causing intussusception in a 25-year-old man: report of a case and review of the literature. BMC Surgery, 2010, $10$ , $19$ .	1.3	26

#	Article	IF	Citations
235	The evidence based dilemma of intraperitoneal drainage for pancreatic resection – a systematic review and meta-analysis. BMC Surgery, 2014, 14, 76.	1.3	26
236	Differentiation of Autoimmune Pancreatitis from Pancreatic Cancer Remains Challenging. World Journal of Surgery, 2019, 43, 1604-1611.	1.6	26
237	Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. American Journal of Surgery, 2002, 184, 78-83.	1.8	25
238	Gefitinib (â€~Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology, 2004, 25, 203.	3.3	25
239	Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. International Journal of Oncology, 2007, 30, 91.	3.3	25
240	Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers. Chemotherapy, 2009, 55, 407-413.	1.6	25
241	The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells. International Journal of Oncology, 2009, 35, 1111-6.	3.3	25
242	Loss of Periostin Results in Impaired Regeneration and Pancreatic Atrophy after Cerulein-Induced Pancreatitis. American Journal of Pathology, 2016, 186, 24-31.	3.8	25
243	Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers, 2021, 13, 697.	3.7	25
244	Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. Anticancer Research, 2003, 23, 2711-6.	1.1	25
245	Adaptation of the human pancreas to inhibition of luminal proteolytic activity. Gastroenterology, 1998, 115, 388-396.	1.3	24
246	Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell International, 2005, 5, 3.	4.1	24
247	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. Abdominal Radiology, 2016, 41, 1937-1941.	2.1	24
248	mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote KrasG12D-Induced Acinar-to-Ductal Metaplasia and Early Pancreatic Carcinogenesis. Gastroenterology, 2021, 160, 1755-1770.e17.	1.3	24
249	COMP is Selectively Up-regulated in Degenerating Acinar Cells in Chronic Pancreatitis and in Chronic-Pancreatitis-like Lesions in Pancreatic Cancer. Scandinavian Journal of Gastroenterology, 2003, 38, 207-215.	1.5	23
250	Pancreatic metastasis of Merkel cell carcinoma and concomitant insulinoma: case report and literature review. World Journal of Surgical Oncology, 2005, 3, 58.	1.9	23
251	The impact factor rankingâ€"a challenge for scientists and publishers. Langenbeck's Archives of Surgery, 2010, 395, 69-73.	1.9	23
252	Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. British Journal of Cancer, 2011, 105, 288-295.	6.4	23

#	Article	IF	Citations
253	Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection. Langenbeck's Archives of Surgery, 2020, 405, 903-919.	1.9	23
254	Update on surgical treatment of pancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2014, 20, 13893.	3.3	23
255	Surgical approaches to chronic pancreatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 167-181.	2.4	22
256	Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 429-449.	4.5	22
257	Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis. BMC Cancer, 2019, 19, 887.	2.6	22
258	Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer. Histology and Histopathology, 2010, 25, 1497-506.	0.7	22
259	Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. International Journal of Molecular Medicine, 2006, 17, 761-7.	4.0	22
260	Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 296-302.	2.8	21
261	Pancreatic anastomosis after pancreaticoduodenectomy: how we do it. Indian Journal of Surgery, 2007, 69, 224-229.	0.3	21
262	Expression of FXYD-3 is an Independent Prognostic Factor in Rectal Cancer Patients With Preoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 137-142.	0.8	21
263	Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbeck's Archives of Surgery, 2012, 397, 507-512.	1.9	21
264	Pancreatic Cancer - New Aspects of Molecular Biology Research. Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera, 2000, 6, 231-234.	0.3	21
265	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Annals of Oncology, 2017, 28, 1618-1624.	1.2	20
266	BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Molecular Cancer, 2007, 6, 83.	19.2	19
267	Identification of Malignancy Factors by Analyzing Cystic Tumors of the Pancreas. Pancreatology, 2009, 9, 34-44.	1.1	19
268	Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology, 2015, 15, 156-161.	1.1	19
269	Umbilical Microflora, Antiseptic Skin Preparation, and Surgical Site Infection in Abdominal Surgery. Surgical Infections, 2015, 16, 450-454.	1.4	19
270	Expression Analysis of PMP22/Gas3 in Premalignant and Malignant Pancreatic Lesions. Journal of Histochemistry and Cytochemistry, 2005, 53, 885-893.	2.5	18

#	Article	IF	CITATIONS
271	Correlation of glypican-1 expression with TGF-Î <sup>2</sup> , BMP, and activin receptors in pancreatic ductal adenocarcinoma. International Journal of Oncology, 2006, 29, 1139.	3.3	18
272	Expression of MAC30 in Rectal Cancers with or without Preoperative Radiotherapy. Oncology, 2006, 71, 259-265.	1.9	18
273	Autologous Serum Improves Yield and Metabolic Capacity of Monocyte-Derived Hepatocyte-Like Cells: Possible Implication for Cell Transplantation. Cell Transplantation, 2011, 20, 1465-1478.	2.5	18
274	Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Oncology Reports, 2012, 28, 2177-2187.	2.6	18
275	A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Scientific Reports, 2015, 5, 8109.	3.3	18
276	Periostin and tumor-stroma interactions in non-small cell lung cancer. Oncology Letters, 2016, 12, 3804-3810.	1.8	18
277	Early Drain Removal is Safe in Patients With Low or Intermediate Risk of Pancreatic Fistula After Pancreaticoduodenectomy. Annals of Surgery, 2022, 275, e307-e314.	4.2	18
278	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 4326.	3.7	18
279	Ligand Induced Upregulation of the Type II Transforming Growth Factor (TGF-β) Receptor Enhances TGF-P Responsiveness in COLO-357 Cells. Pancreas, 1999, 18, 364-370.	1.1	17
280	DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Investigational New Drugs, 2005, 23, 339-347.	2.6	17
281	Postoperative negative-pressure incision therapy following open colorectal surgery (Poniy): study protocol for a randomized controlled trial. Trials, 2015, 16, 471.	1.6	17
282	Pancreatic cancer surgery with vascular resection: current concepts and perspectives. Journal of Pancreatology, 2019, 2, 1-5.	0.9	17
283	Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival. International Journal of Cancer, 2021, 148, 1919-1927.	5.1	17
284	Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Research, 2003, 23, 251-8.	1.1	17
285	Confirmation of DNA Microarray-Derived Differentially Expressed Genes in Pancreatic Cancer Using Quantitative RT-PCR. Pancreatology, 2009, 9, 577-582.	1.1	16
286	Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. International Journal of Oncology, 2009, 35, 823-8.	3.3	16
287	Surgery for Cystic Pancreatic Lesions in the Post-Sendai Era: A Single Institution Experience. HPB Surgery, 2015, 2015, 1-5.	2.2	16
288	Molecular versus Conventional Markers in Pancreatic Cancer. Digestion, 1997, 58, 557-563.	2.3	15

#	Article	IF	Citations
289	Adenovirus-Mediated Transfer of a Truncated Fibroblast Growth Factor (FGF) Type I Receptor Blocks FGF-2 Signaling in Multiple Pancreatic Cancer Cell Lines. Pancreas, 2004, 28, 25-30.	1.1	15
290	Reduced α-Dystroglycan Expression Correlates with Shortened Patient Survival in Pancreatic Cancer. Journal of Surgical Research, 2011, 171, 120-126.	1.6	15
291	Volumetric gain of the human pancreas after left partial pancreatic resection: A CT-scan based retrospective study. Pancreatology, 2015, 15, 542-547.	1.1	15
292	Potential role of Th17 cells in the pathogenesis of type 2 autoimmune pancreatitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 641-648.	2.8	15
293	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Medicine, 2021, 13, 15.	8.2	15
294	The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings. Surgery, 1998, 124, 79-86.	1.9	14
295	Molecular pathophysiology of chronic pancreatitis—an update. Journal of Gastrointestinal Surgery, 2003, 7, 943-945.	1.7	14
296	Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. Cancer Letters, 2007, 245, 171-183.	7.2	14
297	Expression and Significance of FXYD-3 Protein in Gastric Adenocarcinoma. Disease Markers, 2010, 28, 63-69.	1.3	14
298	The actin binding protein destrin is associated with growth and perineural invasion of pancreatic cancer. Pancreatology, 2012, 12, 350-357.	1.1	14
299	Cancer-Associated Fibroblasts and Tumor Cells in Pancreatic Cancer Microenvironment and Metastasis: Paracrine Regulators, Reciprocation and Exosomes. Cancers, 2022, 14, 744.	3.7	14
300	How <i>Helicobacter pylori</i> Changed the Life of Surgeons. Digestive Surgery, 2003, 20, 93-102.	1.2	13
301	Early drain removal after major pancreatectomy reduces postoperative complications: a single-center, randomized, controlled trial. Journal of Pancreatology, 2020, 3, 93-100.	0.9	13
302	Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. Cancers, 2021, 13, 4391.	3.7	13
303	Clinical Outcomes after Total Pancreatectomy. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	13
304	Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Disease Markers, 2010, 28, 63-9.	1.3	13
305	Timing and Extent of Surgical Intervention in Patients from Hereditary Pancreatic Cancer Kindreds. Pancreatology, 2001, 1, 525-530.	1.1	12
306	A Chair Leg as the Rare Cause of a Transabdominal Impalement with Duodenal and Pancreatic Involvement. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 51, 164-167.	2.4	12

#	Article	IF	Citations
307	T1 Pancreatic Cancer With Lymph Node Metastasis and Perineural Invasion of the Celiac Trunk. Clinical Gastroenterology and Hepatology, 2008, 6, e41-e42.	4.4	12
308	Outcome after surgery for acute right-sided colonic ischemia without feasible vascular intervention: a single center experience of 58 patients over 6 years. BMC Surgery, 2015, 15, 31.	1.3	12
309	Response evaluation following neoadjuvant treatment of pancreatic cancer patients. World Journal of Gastrointestinal Surgery, 2013, 5, 12.	1.5	12
310	Loss of ONECUT1 expression in human pancreatic cancer cells. Oncology Reports, 2008, 19, 157-63.	2.6	12
311	Management of Hepatobiliary Cystadenocarcinoma. Digestive Surgery, 2003, 20, 60-63.	1.2	11
312	Preoperative Acute Pancreatitis in Periampullary Tumors: Implications for Surgical Management. Digestion, 2007, 75, 165-171.	2.3	11
313	Resection of the intrapancreatic bile duct preserving the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2009, 16, 31-34.	2.0	11
314	Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial. Trials, 2012, 13, 57.	1.6	11
315	Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. Molecular Cancer, 2015, 14, 212.	19.2	11
316	Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncology, The, 2017, 18, 421-422.	10.7	11
317	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case–control approaches. International Journal of Cancer, 2019, 144, 1540-1549.	5.1	11
318	Tumor initiating cells in pancreatic cancer: A critical view. World Journal of Stem Cells, 2009, 1, 8.	2.8	11
319	KAI1 inhibits anchorage-dependent and -independent pancreatic cancer cell growth. Oncology Reports, 2005, 14, 59-63.	2.6	11
320	Influence of High-Dose Pancreatic Enzyme Treatment on Pancreatic Function in Healthy Volunteers. International Journal of Gastrointestinal Cancer, 1998, 23, 115-124.	0.4	10
321	Expression of cytokeratin-20 in pancreatic cancer: An indicator of poor outcome after RO resection. Surgery, 2006, 139, 104-108.	1.9	10
322	Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer. Cancers, 2011, 3, 652-661.	3.7	10
323	Preoperative Serum Bilirubin and Lactate Levels Predict Postoperative Morbidity and Mortality in Liver Surgery: A Single-Center Evaluation. Scandinavian Journal of Surgery, 2015, 104, 176-184.	2.6	10
324	AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Gastroenterology, 2021, 161, 1601-1614.e23.	1.3	10

#	Article	IF	Citations
325	Natural orifice transluminal endoscopic surgery in pancreatic diseases. World Journal of Gastroenterology, 2010, 16, 3859.	3.3	10
326	Immunohistochemical presentation in non-malignant and malignant Barrett's epithelium*. Ecological Management and Restoration, 2002, 15, 10-15.	0.4	9
327	The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterology, 2005, 5, 20.	2.0	9
328	Loss of ONECUT1 expression in human pancreatic cancer cells. Oncology Reports, 0, , .	2.6	9
329	Transarterial Chemoembolization of Liver Metastases As Symptomatic Therapy of Lipase Hypersecretion Syndrome. Journal of Clinical Oncology, 2012, 30, e209-e212.	1.6	9
330	Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. BMC Surgery, 2015, 15, 100.	1.3	9
331	Co-Existent Chronic Pancreatitis and Pancreatic Neuroendocrine Tumor. Pancreatology, 2001, 1, 117-122.	1.1	8
332	Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. International Journal of Molecular Medicine, 2006, 17, 761.	4.0	8
333	Dissection of the uncinate process and pancreatic head behind the portal vein using endovascular staplers. Journal of Hepato-Biliary-Pancreatic Surgery, 2007, 14, 480-483.	2.0	8
334	Beger's operation and the Berne modification: origin and current results. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 735-744.	2.6	8
335	Management problems in patients with pancreatic cancer from a surgeon's perspective. Seminars in Oncology, 2021, 48, 76-83.	2.2	8
336	Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells. Molecular Medicine Reports, 2016, 14, 3627-3633.	2.4	7
337	In vivo functional dissection of a context-dependent role for Hif1 $\hat{l}\pm$ in pancreatic tumorigenesis. Oncogenesis, 2016, 5, e278-e278.	4.9	7
338	Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?. EClinicalMedicine, 2019, 17, 100222.	7.1	7
339	Gene-expression analysis of single cells-nested polymerase chain reaction after laser microdissection. World Journal of Gastroenterology, 2003, 9, 1337.	3.3	7
340	Acute and chronic mesenteric ischemia: single center analysis of open, endovascular, and hybrid surgery. BMC Surgery, 2022, 22, 56.	1.3	7
341	Bile duct infarction following intraarterial hepatic chemotherapy mimicking multiple liver metastasis: report of a case and review of the literature. Digestive Diseases and Sciences, 2002, 47, 338-344.	2.3	6
342	Solid type clear cell carcinoma of the pancreas: differential diagnosis of an unusual case and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 719-726.	2.8	6

#	Article	IF	Citations
343	Approaches to localized pancreatic cancer. Current Oncology Reports, 2008, 10, 212-219.	4.0	6
344	Nonmetastatic Pancreatic Cancer: Many Trials, Little Progress. Journal of Clinical Oncology, 2008, 26, 3100-3100.	1.6	6
345	Loss of TLR3 and its downstream signaling accelerates acinar cell damage in the acute phase of pancreatitis. Pancreatology, 2019, 19, 149-157.	1.1	6
346	Synchronous arterial resections in pancreatic cancer – still a matter of debate?. European Journal of Surgical Oncology, 2021, 47, 480-482.	1.0	6
347	Surgical approaches for resection of pancreatic cancer: an overview. Hepatobiliary and Pancreatic Diseases International, 2002, 1, 118-25.	1.3	6
348	Tumor metabolism to blood flow ratio in pancreatic cancer: helpful in patient stratification?. Future Oncology, 2010, 6, 13-15.	2.4	5
349	Manufacturing of patient-specific pancreas models for surgical resections. , 2012, , .		5
350	Could hyponatremia be a marker of anastomotic leakage after colorectal surgery? A single center analysis of 1,106 patients over 5Âyears. Langenbeck's Archives of Surgery, 2014, 399, 783-788.	1.9	5
351	Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways. Scientific Reports, 2018, 8, 11894.	3.3	5
352	Ductal obstruction promotes formation of preneoplastic lesions from the pancreatic ductal compartment. International Journal of Cancer, 2019, 144, 2529-2538.	5.1	5
353	OUP accepted manuscript. British Journal of Surgery, 2021, , .	0.3	5
354	Molekulare VerÄ <b>n</b> derungen bei Pankreas- und periampullÄ <b>n</b> en Karzinomen. Visceral Medicine, 1999, 15, 150-157.	1.3	4
355	Local pancreatic resection with preoperative endoscopic transpapillary stenting. American Journal of Surgery, 2007, 194, 311-312.	1.8	4
356	Loss of Ifnar1 in Pancreatic Acinar Cells Ameliorates the Disease Course of Acute Pancreatitis. PLoS ONE, 2015, 10, e0143735.	2.5	4
357	Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis. Pancreatology, 2020, 20, 1673-1681.	1.1	4
358	Sca-1 is a marker for cell plasticity in murine pancreatic epithelial cells and induced by IFN-β inÂvitro. Pancreatology, 2022, , .	1.1	4
359	Detection of oncogenes in chronic pancreatitis. Hpb, 2003, 5, 214-225.	0.3	3
360	Molecular biology, models, and histopathology of chronic pancreatitis and pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2009, 41, 250-267.	0.7	3

#	Article	IF	Citations
361	Defining New Pancreatic Tumour Entities by Molecular Analysis. Pancreatology, 2009, 9, 334-339.	1.1	3
362	Level of hospital care and outcome of gastric cancer: a population-based evaluation of the Munich Cancer Registry. Journal of Cancer Research and Clinical Oncology, 2014, 140, 789-800.	2.5	3
363	Metabolism gene signatures and surgical site infections in abdominal surgery. International Journal of Surgery, 2015, 14, 67-74.	2.7	3
364	Pathobiology of pancreatic cancer: implications on therapy. Expert Review of Anticancer Therapy, 2016, 16, 219-227.	2.4	3
365	Pancreatic Cancer and FOLFIRINOX. Annals of Surgery, 2018, 267, e35-e36.	4.2	3
366	Current concepts and evidence on open, endovascular and hybrid treatment of mesenteric ischemia: The retrograde open mesenteric stenting. Surgery in Practice and Science, 2021, 5, 100022.	0.4	3
367	Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 211-213.	0.2	3
368	Surgical Oncology: Multidisciplinarity to Improve Cancer Treatment and Outcomes. Current Oncology, 2021, 28, 4471-4473.	2.2	3
369	Role of Positron Emission Tomography in Diagnosis of Pancreatic Cancer and Cancer Recurrence. , 0, , 648-657.		3
370	What is the most accurate test to differentiate pancreatic cystic neoplasms?. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 18-19.	1.7	2
371	Multidisciplinary Treatment of Aggressive and Rapidly Progressing Biliary Papillomatosis. Digestive Diseases and Sciences, 2010, 55, 3627-3629.	2.3	2
372	Further characterization of autologous NeoHepatocytes for in vitro toxicity testing. Toxicology in Vitro, 2011, 25, 1203-1208.	2.4	2
373	Massive intra-abdominal bleeding caused by nontraumatic rupture of a vein in the colorenal ligament: Report of a case. Surgery Today, 2011, 41, 415-417.	1.5	2
374	EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease. Public Health Genomics, 2013, 16, 305-312.	1.0	2
375	Precision oncology for pancreatic cancer in real-world settings. Lancet Oncology, The, 2020, 21, 469-471.	10.7	2
376	Do arterial resections improve survival in pancreatic cancer?â€"a narrative review. Chinese Clinical Oncology, 2021, 10, 48-48.	1.2	2
377	Surgery With Arterial Resection for Hilar Cholangiocarcinoma: Protocol for a Systematic Review and Meta-analysis. JMIR Research Protocols, 2021, 10, e31212.	1.0	2
378	Tumor-Stromal Interactions in Invasion and Metastases. , 2010, , 535-563.		2

#	Article	IF	Citations
379	Systematic review and meta-analysis of surgery for hilar cholangiocarcinoma with arterial resection. Hpb, 2022, 24, 1600-1614.	0.3	2
380	Expression of the Shwachman-Bodian-Diamond syndrome (SBDS) protein in human pancreatic cancer and chronic pancreatitis. Histology and Histopathology, 2008, 23, 819-26.	0.7	2
381	Differential localization and activation of mast cells in chronic pancreatitis of different etiologies. Gastroenterology, 2001, 120, A645.	1.3	1
382	Molecular alterations in chronic pancreatitis. Journal of Hepato-Biliary-Pancreatic Surgery, 2002, 9, 653-658.	2.0	1
383	Adenovirus mediated transfer of a truncated fibroblast growth factor (FGF) typ I receptor blocks FGF2 signaling in pancreatic cancer cells. Gastroenterology, 2003, 124, A104.	1.3	1
384	Activation of growth factor receptors in pancreatic cancer. American Journal of Surgery, 2007, 194, S76-S83.	1.8	1
385	AMPA RECEPTOR ANTAGONISM INHIBITS PANCREATIC CANCER GROWTH. Pancreas, 2008, 37, 485.	1.1	1
386	Re: Distal Pancreatectomy. Annals of Surgery, 2008, 247, 393.	4.2	1
387	First case of spontaneous myospherulosis of the liver. Journal of Clinical Pathology, 2013, 66, 161-163.	2.0	1
388	Minimalinvasive Chirurgie bei Malignomen des Gastrointestinaltrakts: Kolon - Pro-Position. Visceral Medicine, 2013, 29, 382-387.	1.3	1
389	Minimalinvasive Chirurgie bei Malignomen des Gastrointestinaltrakts: Pankreas - Kontra-Position. Visceral Medicine, 2013, 29, 375-381.	1.3	1
390	RE: Proteomic Mucin Profiling for the Identification of Cystic Precursors of Pancreatic Cancer. Journal of the National Cancer Institute, 2014, 106, dju263-dju263.	6.3	1
391	Arterial Resection in Pancreatic Cancer. , 2016, , 1-16.		1
392	Obstructive pancreatitis is a stronger fibrogenic stimulus than cancer-specific stellate cell activation in pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, S36-S37.	1.1	1
393	Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma―by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS. Annals of Surgery. 2019. 270. e130-e131.	4.2	1
394	Multimodal Therapy of Upper Gastrointestinal Malignancies. Cancers, 2021, 13, 793.	3.7	1
395	Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA). The Cochrane Library, 0, , .	2.8	1
396	The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis. Langenbeck's Archives of Surgery, 2021, , 1.	1.9	1

#	Article	IF	Citations
397	Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. , 2000, 86, 399.		1
398	Asymptomatic pancreatic lesions: New insights and clinical implications. World Journal of Gastroenterology, 2012, 18, 4474.	3.3	1
399	Complexity of molecular alterations impacts pancreatic cancer prognosis. World Journal of Gastrointestinal Oncology, 2013, 5, 1.	2.0	1
400	Interventions to reduce the incidence of surgical site infection in colorectal resections: systematic review with multicomponent network meta-analysis (INTRISSI): study protocol. BMJ Open, 2021, 11, e057226.	1.9	1
401	Intracystic Papillary Neoplasm of the Gallbladder. Journal of Gastrointestinal Surgery, 2022, 26, 982-984.	1.7	1
402	Lymph Node Yield in Gastrointestinal Cancer Surgery With or Without Prior Neoadjuvant Therapy: Protocol for a Systematic Review and Meta-analysis. JMIR Research Protocols, 2022, 11, e35243.	1.0	1
403	Management of an abdominal penetration injury due to a car accident. Trauma Case Reports, 2022, 39, 100646.	0.4	1
404	Transcriptional up-regulation of transforming growth factor- $\hat{l}^2$ (TGF- $\hat{l}^2$ ) receptors by TGF- $\hat{l}^2$ 1 correlates with expression of cyclin d-dependent kinase inhibitors. Gastroenterology, 1998, 114, A626.	1.3	0
405	Gentherapie bei gastrointestinalen Tumoren am Beispiel des Pankreaskarzinoms: Standortbestimmung und Perspektiven. Visceral Medicine, 1999, 15, 181-187.	1.3	O
406	Glypican-3 is a potential tumor marker for hepatocellular carcinoma. Gastroenterology, 2000, 118, A261.	1.3	0
407	Increased sensitivity to gemcitabine following Bcl-xL antisense treatment in pancreatic cancer cells. Gastroenterology, 2000, 118, A521.	1.3	0
408	Reduction of the angiostatic chemokine SF-1 and concomitant increase of its receptor CXCR-4 in colorectal cancer. Gastroenterology, 2000, 118, A769.	1.3	0
409	Connective tissue growth factor as an inducer of fibrosis in human liver cirrhosis. Gastroenterology, 2000, 118, A452.	1.3	O
410	The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer. Gastroenterology, 2001, 120, A160.	1.3	0
411	"How I Do It―session: pancreatitis—molecular biology update. Journal of Gastrointestinal Surgery, 2003, 7, 939.	1.7	O
412	Pancreatic fistula after pancreatic head resection: A problem of the past?. Gastroenterology, 2003, 124, A822.	1.3	0
413	Disturbance of the substance P/neurokinin receptor $1$ pathway in inflammatory bowel disease. Gastroenterology, 2003, 124, A334.	1.3	0
414	Central pancreatic head resection in chronic pancreatitis ȕa new simple surgical approach to solve head related complications: First results of a phase I prospective evaluation. Gastroenterology, 2003, 124, A821.	1.3	0

#	Article	IF	CITATIONS
415	DISTINCT EXPRESSION OF CXC CHEMOKINES IN HUMAN PANCREATIC CANCER TISSUES Pancreas, 2004, 29, 358.	1.1	0
416	LOCALIZATION OF THE HUMAN HEDGEHOG-INTERACTING PROTEIN (HIP) IN THE NORMAL AND DISEASED PANCREAS Pancreas, 2004, 29, 327.	1.1	0
417	Current status on molecular markers and targets in pancreatic disease. European Journal of Cancer, Supplement, 2006, 4, 11.	2.2	O
418	P10. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. European Journal of Cancer, Supplement, 2006, 4, 30-31.	2.2	0
419	Chronische Pankreatitis und Schmerz – chirurgische Sicht. Visceral Medicine, 2006, 22, 21-26.	1.3	0
420	ADRENOMEDULLIN (ADM) IS INDUCED BY HYPOXIA AND ENHANCES PANCREATIC CANCER CELL INVASION. Pancreas, 2006, 33, 474-475.	1.1	0
421	GUEST EDITORIAL. Hpb, 2006, 8, 323.	0.3	0
422	What is the best strategy for the surgical management of patients with necrotizing pancreatitis?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 616-617.	1.7	0
423	INTERLEUKIN-13 EXERTS AUTOCRINE GROWTH PROMOTING EFFECTS IN HUMAN PANCREATIC CANCER AND ITS EXPRESSION CORRELATES WITH A PROPENSITY FOR LYMPH NODE METASTASES. Pancreas, 2007, 35, 402.	1.1	0
424	3513 POSTER Interleukin-13 exerts autocrine growth promoting effects in human pancreatic cancer and its expression correlates with a propensity for lymph node metastases. European Journal of Cancer, Supplement, 2007, 5, 263.	2.2	0
425	Hepatobiliary and pancreatic: Autoimmune pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 592-592.	2.8	O
426	Pancreatic cancer â€" Curative resection. Chinese-German Journal of Clinical Oncology, 2007, 6, 149-153.	0.1	0
427	Pancreatic cancer — Surgery for recurrent disease. Chinese-German Journal of Clinical Oncology, 2007, 6, 159-161.	0.1	O
428	Management postoperativer und postinterventioneller Gallenwegskomplikationen. Chirurgische Gastroenterologie Interdisziplinar, 2008, 24, 115-123.	0.0	0
429	CANCER-STELLATE CELL INTERACTIONS INHIBIT ANGIOGENESIS AND PERPETUATE THE HYPOXIA-FIBROSIS CYCLE IN PANCREATIC CANCER. Pancreas, 2008, 37, 469.	1.1	О
430	Comparative analysis of the revenues of pylorus-preserving pancreatic head resections and laparoscopic cholecystectomies as prototypic surgical procedures in the German health-care system. Langenbeck's Archives of Surgery, 2013, 398, 825-831.	1.9	0
431	Loss of Ppar-gamma promotes KrasG12D-driven pancreatic ductal adenocarcinoma formation by inhibiting p53 function. Pancreatology, 2013, 13, S57-S58.	1.1	О
432	Pancreaticoduodenectomy in patients with true cancer infiltration of the portal vein is associated with an unfavorable prognosis. Pancreatology, 2013, 13, e4.	1.1	0

#	Article	IF	Citations
433	Analysis of the extracellular matrix protein periostin in early pancreatic carcinogenesis. Pancreatology, 2013, 13, S14-S15.	1.1	0
434	Epigenetic changes mediated by the polycomb repressor complex 1 in acinar-to-ductal metaplasia and pancreatic carcinogenesis Pancreatology, 2014, 14, S64.	1.1	0
435	675: Therapeutic and diagnostic targeting of gastrointestinal tumors with Shiga Toxin B subunit. European Journal of Cancer, 2014, 50, S163.	2.8	0
436	O170 DYSREGULATED UNFOLDED PROTEIN RESPONSE CONTROL IN THE ABSENCE OF CANONICAL IKK/NF-κB SIGNALLING LEADS TO SEVERE LIVER DAMAGE AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S526.	3.7	0
437	Epigenetic changes mediated by the polycomb repressor complex 1 in acinar-to-ductal metaplasia and pancreatic carcinogenesis. Pancreatology, 2015, 15, S44.	1.1	0
438	Periostin promotes pancreatic carcinogenesis and metastatic spread. Pancreatology, 2015, 15, S33.	1.1	0
439	P0284 : Type 2 diabetes promotes hepatocarcinogenesis by inhibiting the induction of senescence after DNA damage. Journal of Hepatology, 2015, 62, S414.	3.7	0
440	Peer review report 2 on "Treatment of choledochal cyst in a pediatric population. A single institution experience of 15-years. Case series― Annals of Medicine and Surgery, 2016, 5, S55.	1.1	0
441	Peer review report 3 on "Evaluation of the minimally invasive parathyroidectomy in patients with primary hyperparathyroidism: A retrospective cohort studyâ€. Annals of Medicine and Surgery, 2016, 5, S113.	1.1	0
442	Assessment of Response to Preoperative Therapy. , 2016, , 143-157.		0
443	Peer review report 1 on "Safety and feasibility of single-incision laparoscopic cholecystectomy in obese patients― Annals of Medicine and Surgery, 2017, 13, 57.	1.1	0
444	Severe Colitis After an Alcohol Enema. American Journal of Gastroenterology, 2018, 113, 172.	0.4	0
445	Arterial Resection in Pancreatic Cancer. , 2018, , 1089-1104.		0
446	Analyzing the impact of epigenetic profiles on the reprogramming efficiency in different pancreatic cancer subtypes. Pancreatology, 2019, 19, S82.	1.1	0
447	Surgery for Pancreatic Cancer., 2020, , 576-586.		0
448	Hepatic activation of FOXO3 triggers positive feedback-loop for mTORC2-Akt and enhances oxidative damage-associated hepatocellular carcinogenesis. Journal of Hepatology, 2020, 73, S652.	3.7	0
449	Surgery in practice and science. Surgery in Practice and Science, 2020, 1, 100003.	0.4	0
450	Types of Pancreatic Resections. Encyclopedia of Pathology, 2021, , 1-6.	0.0	0

#	Article	IF	CITATIONS
451	Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. European Journal of Cancer Prevention, 2021, 30, 423-430.	1.3	O
452	Hepatic Activation of FOXO3 Is Associated with Pentose Phosphate Pathway Activation as Well as mTORC2-Akt Signaling and Enhances Oxidative Damage-Associated Hepatocellular Carcinogenesis. Hpb, 2021, 23, S138-S139.	0.3	0
453	Vascular Resections in Surgery for Pancreatic Cancer. Encyclopedia of Pathology, 2021, , 1-5.	0.0	0
454	Anatomic Variants. Encyclopedia of Pathology, 2021, , 1-6.	0.0	0
455	The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer. Gastroenterology, 2001, 120, A160-A160.	1.3	O
456	Differential localization and activation of mast cells in chronic pancreatitis of different etiologies. Gastroenterology, 2001, 120, A645-A645.	1.3	0
457	Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gastroesophageal junction. World Journal of Gastroenterology, 2009, 15, 3065.	3.3	0
458	HED., 2009, , 787-787.		0
459	Langzeitverlauf der Autoimmunpankreatitis. , 2013, , 176-180.		0
460	Clinical Applicability of Molecular Procedures in the Diagnosis of Pancreatic Cancer., 1997,, 411-423.		0
461	Abstract B08: The role of periostin in pancreatic carcinogenesis and metastatic spread. , 2015, , .		0
462	Abstract B01: Epigenetic alterations mediated by Ring1b are crucial for a cinar-to-ductal metaplasia and pancreatic carcinogenesis. , 2016, , .		0
463	Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. Minerva Surgery, 2017, 72, 424-431.	0.6	0
464	Pancreatic carcinoma: surgery, palliative resection and value of lymph node resection., 0,, 114-119.		0
465	Die Entwicklung des "Europ¤chen Pankreaszentrums Heidelberg" (EPZ). , 2007, , 109-126.		0
466	Acute Necrotizing Pancreatitis Post-Pancreatoduodenectomy., 2020,, 259-262.		0
467	Palliative Pancreaticoduodenectomy: Benefits and Limitations. , 0, , 714-718.		0
468	Management of Cancer Recurrence., 0,, 772-775.		0